Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Forbion Capital Partners. (3/14/22). "Press Release: Forbion Strengthens Its Team with the Appointments of Mathias Vinther and Vanessa Carle". Naarden.

Products Product venture capital
Person Person Vinther, Mathias (Forbion 202203– Principal before Novo Ventures since 2016)

Forbion today announces the appointments of Mathias Vinther as Principal and Vanessa Carle as Associate. Mathias will be focusing on Forbion’s Growth Fund while Vanessa will be working across Forbion’s strategies.

Mathias joins Forbion from Novo Ventures, which he joined in 2016. At Novo, he led due diligence on a dozen biotech companies across Europe, including success stories such as Therachon which was acquired by Pfizer, and NBE Therapeutics which was bought by Boehringer Ingelheim, as well as four NASDAQ IPOs: VectivBio, Inventiva, Pharvaris and Lava Therapeutics. Moreover, he supported several Novo Ventures portfolio companies operationally with their corporate and reimbursement strategies, refinancing, business development and exit trajectories. Mathias holds a PhD in Nanomedicine with an emphasis on Immunotherapy and Drug Delivery from Aarhus University. Mathias also studied at Berkeley and Harvard Medical School.

Vanessa joins Forbion from PharmaVentures where she was an Associate responsible for assisting clients with BD & L activities and corporate strategy. Prior to PharmaVentures, Vanessa worked at the Swiss Federal Institute of Technology Lausanne (EPFL) as a scientist and co-Principal Investigator for a translational drug development project. She also brings experience in mentoring early-stage healthcare spin-off projects with business accelerators such as MassChallenge and Bench2biz, for aspiring entrepreneurs in science and technology. Vanessa holds a BSc in Biotechnology from the University of Pavia in Italy, an MSc in Pharmaceutical Biotechnology from the Martin Luther University Halle-Wittenberg in Germany, and a PhD in Chemical Biology with a focus on peptide drug discovery from EPFL in Switzerland.

Mathias Vinther, Principal at Forbion comments: “I am very excited to join the team at Forbion, well known as one of Europe’s leading life sciences venture capital firms and recognised globally. I look forward to working on both the current and next Forbion Growth Opportunities Fund, where I will contribute to building a portfolio of investments in the most promising later-stage, European life sciences companies”.

Vanessa Carle, Associate at Forbion commented: “I am very happy to have joined Forbion and look forward to sharing my knowledge and becoming involved in the investment process. What attracted me to Forbion was the company’s reputation for company building and for providing excellent support to its portfolio companies and entrepreneurs, enabling them to succeed.”

Sander Slootweg, Managing Partner at Forbion adds: “We are delighted to welcome Vanessa and Mathias to Forbion. As we are rapidly expanding our team and business, it is great to be able to attract such talented professionals who can hit the ground running and can immediately start to contribute their complementary skills and experience to our team.”


Record changed: 2023-06-05


Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

More documents for Forbion (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

» top